Have core biopsy or other minor surgical procedures within  days prior to the first dose of bevacizumab
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day 
Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within  days of day 
Minor surgical procedure (e.g., stereotactic biopsy within  days of first study treatment; placement of a vascular access device within  days of first study treatment).
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day 
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day  of FOLFIRI + bevacizumab initiation
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to Day 
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to study enrollment
Patients are excluded if they have had a biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to randomization
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  calendar days prior to the first dose of bevacizumab
Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within  days of day 
Core biopsy or other minor surgical procedure (excluding placement of a vascular access device, paracentesis, and/or thoracentesis) within  days prior to the first date of bevacizumab therapy
Patients must not have experienced a core biopsy or other minor surgical procedure within  days prior to registration; NOTE: this excludes placement of a vascular access device up to  days prior to registration
Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) within  days of day 
Less than  days have passed from core biopsies or other minor surgical procedures excluding placement of a vascular access device
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day 
Care biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day ; (minor surgical procedures include minimally invasive procedures such as fine needle aspiration, core biopsy, etc. requiring little if any supportive care excluding lumbar puncture and bone marrow aspiration/biopsy)
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day 
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device within  days prior to starting drug
(continued from no. ) Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to the first date of bevacizumab therapy
Minor surgical procedure(s) within  days of enrollment or not yet recovered from prior minor surgery (placement of central venous access device, fine needle aspiration, or endoscopic biliary stent ?  day before enrollment is acceptable)
Any surgical procedure, excluding central venous catheter placement, bone marrow biopsy, lumbar puncture, or other minor procedures (e.g., skin biopsy) within  days of day ; patients who have undergone major surgery =<  days prior to starting study drug or who have not recovered from side effects of such procedure are ineligible for the study
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to Day 
Patients may not have had a core biopsy, skin cancer resection, or other minor surgical procedure, including placement of a vascular access device, within  days prior to Day  of the protocol.
Bleeding risks: Required to be on therapeutic anticoagulation (aspirin is allowed), coagulopathy (e.g. hemophilia or von Willebrand's disease); any grade III or greater hemorrhage, major surgical procedure, or significant trauma within  days; core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days
Core biopsy or other minor surgical procedure within  days prior to study start
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to day 
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within  days prior to the first dose of bevacizumab or vanucizumab